A novel three-drug combination achieved notable responses in patients with advanced HER2-negative breast cancer, according to new research directed by investigators from the Johns Hopkins Kimmel Cancer Center.
A novel three-drug combination achieved notable responses in patients with advanced HER2-negative breast cancer, according to new research directed by investiga
A novel three-drug combination achieved notable responses in patients with advanced HER2-negative breast cancer, according to new research directed by investiga
Combining a histone deacetylase inhibitor drug with immunotherapy agents is safe, and may benefit some patients with advanced cancers that have not responded to traditional therapy, according to results of a phase 1 clinical trial led by researchers